Gainers

• Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday's pre-market session. The company's market cap stands at $1.1 million. As per the press release, H1 earnings came out 2 days ago.
• Vera Therapeutics (NASDAQ:VERA) stock increased by 14.53% to $39.0. The company's market cap stands at $2.4 billion.
• Akari Therapeutics (NASDAQ:AKTX) shares moved upwards by 14.31% to $12.62. The company's market cap stands at $21.4 million.
• Waystar Holding (NASDAQ:WAY) shares rose 12.65% to $28.05. The market value of their outstanding shares is at $4.7 billion.
• PDS Biotechnology (NASDAQ:PDSB) shares rose 11.92% to $0.45. The company's market cap stands at $22.3 million.
• Tenon Medical (NASDAQ:TNON) stock moved upwards by 11.33% to $6.19. The market value of their outstanding shares is at $3.7 million.

Losers

• Connect Biopharma Hldgs (NASDAQ:CNTB) shares declined by 36.2% to $1.1 during Tuesday's pre-market session. The company's market cap stands at $108.6 million.
• Scinai Immunotherapeutics (NASDAQ:SCNI) shares declined by 23.78% to $1.86. The company's market cap stands at $1.6 million.
• Q/C Technologies (NASDAQ:QCLS) stock fell 17.59% to $0.46. The market value of their outstanding shares is at $4.5 million.
• Basel Medical Group (NASDAQ:BMGL) stock declined by 14.57% to $6.1. The market value of their outstanding shares is at $11.1 million.
• Silexion Therapeutics (NASDAQ:SLXN) shares fell 13.78% to $0.33. The company's market cap stands at $2.1 million.
• EUDA Health Holdings (NASDAQ:EUDA) shares fell 12.44% to $14.5. The company's market cap stands at $49.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.